“SSIs are not designed for incremental improvements to the ‘standard of treatment’ – they are designed to re-invent, complement and replace the standard.”
– Dr. Simon Sutcliffe, Chief Medical Officer, Qu Biologics
Supported by a committed group of investors
Qu Biologics is a private clinical-stage biotechnology company incorporated September 2007 in the province of British Columbia, Canada. Qu Biologics has raised $14.5M to date from high net worth individuals and angel investors and an additional $2.7M in federal Canadian government funding through the National Research Council Industrial Research Assistance Program (NRC-IRAP) and the Scientific Research and Experimental Development (SR&ED) Tax Incentive Program.
We believe that SSIs have the potential to revolutionize the treatment of cancer, Crohn’s disease, ulcerative colitis, multiple sclerosis, Alzheimer’s disease, rheumatoid arthritis and other chronic inflammatory diseases by restoring normal immune function and the body’s innate capacity to heal. We are passionate and innovative and committed to creating a team of excellence to achieve this goal and the potential of SSIs.
If you would like to learn more about the investment potential of Qu, we would like to hear from you. We are seeking additional funds and/or a pharmaceutical partnership to expand our clinical trial program to include additional indications in cancer (e.g., late-stage colon cancer, inoperable pancreatic cancer) and immune-related disease (e.g., rheumatoid arthritis), and to finance the large-scale manufacturing of our lead candidate SSIs and Phase 3 multi-national clinical trials.
Rather than blocking or stimulating a specific receptor or pathway, SSI treatments are designed to restore the body’s normal immune response. We believe this new approach will revolutionize the way chronic disease is treated. If you are interested in investment opportunities and learning more about our novel treatment approach and the innovative team behind it, please enter your contact information here.